Mission Statement, Vision, & Core Values (2026) of Hunan Jiudian Pharmaceutical Co., Ltd.

Founded in 2001, Hunan Jiudian Pharmaceutical Co., Ltd. has grown into a national high‑tech enterprise that operates over 200 production lines and employs more than 2,100 staff-including a research force of 400+-while exporting products to over 60 countries and supplying more than 4,000 grade‑A hospitals and China's top 100 pharmacy chains; with a mission that "Health is our mission, and life depends on it," a vision to integrate Chinese and Western medicines and lead in percutaneous drug delivery, strategic partnerships with 10+ research institutions (including Tsinghua and Zhejiang), a commitment to social responsibility and inclusivity, and a proven regulatory record (U.S. FDA on‑site inspection with zero 483 observations), Jiudian reinforced its innovative edge by investing approximately 7.5% of total revenue in R&D in 2022 and climbed to 76th on the 2024 Hunan Top 100 Manufacturing list-up 10 places-setting the stage for deeper exploration of its mission, vision, and core values.

Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ) - Intro

• Founded: 2001; recognized national high-tech enterprise.
• Business scope: R&D, production and sales of finished products, APIs, excipients, traditional Chinese medicines, and nutritional supplements.
• Industrial footprint: Integrated chain covering APIs → excipients → finished products; export markets exceed 60 countries and regions.
• Manufacturing capacity: More than 200 production lines; workforce over 2,100 employees; R&D team exceeds 400 professionals.
• Clinical & commercial reach: Products carried by >4,000 grade-A hospitals and top 100 pharmacy chains in China.
• Regulatory & quality milestones: Passed U.S. FDA on-site inspection with zero 483 observations; holds official certifications from multiple countries.
• Recent recognition: Ranked 76th on the 2024 Hunan Top 100 Manufacturing Enterprises (up 10 places year-over-year).

• Deliver safe, affordable and effective pharmaceutical and healthcare products that improve patient outcomes worldwide.
• Advance integrated pharmaceutical innovation from API to finished product while upholding stringent quality and compliance standards.

• Become a globally recognized, innovation-led pharmaceutical enterprise that shapes modern medicine and TCM integration through a full industrial chain.
• Expand sustainable global presence, serving patients across 100+ markets while driving value for stakeholders and communities.

• Quality First - uncompromising GMP-level standards and regulatory compliance (demonstrated by zero 483 from U.S. FDA).
• Innovation Driven - substantial R&D investment and a 400+ strong research team to accelerate pipeline and formulation advances.
• Integrity & Responsibility - ethical supply, patient safety and transparent governance.
• Collaborative Partnership - build long-term alliances across hospitals, pharmacy chains, distributors and international regulators.
• Sustainability & Social Contribution - local employment, industrial upgrade, and contributions to regional manufacturing rankings.

• Scale manufacturing efficiency across 200+ production lines to support domestic and export demand.
• Expand R&D output: prioritize high-value APIs, novel excipients and TCM-derived therapeutics with clear regulatory pathways.
• Deepen market penetration in existing 60+ export markets and target new territories to increase global revenue share.
• Strengthen hospital and retail channel relationships to drive formulary adoption and brand presence in China's 4,000+ grade-A hospitals and top pharmacy chains.

Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ) - Overview

• Core mission statement: 'Health is our mission, and life depends on it.'
• Strategic focus: integration of traditional Chinese medicine (TCM) and Western pharmaceuticals for holistic treatment portfolios.
• R&D commitment: allocated approximately 7.5% of total revenue to R&D in 2022.
• Collaborative ecosystem: partnerships with over 10 research institutions, including Tsinghua University and Zhejiang University.

• Quality assurance: stringent GMP-aligned manufacturing and quality control systems to ensure safety and efficacy.
• Innovation pipeline: sustained investment in drug discovery, formulation optimization, and clinical validation supported by academic partnerships.
• Societal impact targets: expanding availability of integrated TCM-Western therapies to meet demographic and epidemiological trends.

Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ) - Mission Statement

• Mission focus: combine TCM heritage with modern formulation technologies to expand percutaneous therapeutics availability and efficacy.
• Strategic priorities: innovation in transdermal delivery, regulatory-grade manufacturing, and market penetration in China's dermatological and systemic-patch segments.
• Quality commitment: adhere to GMP, ISO-aligned quality systems, and evidence-based clinical validation for new preparations.

• "Integrating Chinese and Western Medicines, Committed to Health." - a guiding vision to fuse traditional pharmacopoeia with contemporary pharmaceutical science.
• Aspire to be a leading enterprise in percutaneous drug delivery in China, expanding from specialty patches to platform technologies for systemic and local drug administration.
• Leverage a comprehensive pipeline emphasizing transdermal drug delivery and high-end preparations to drive sustainable growth and therapeutic impact.

• National high-tech enterprise designation (awarded 2017) recognizing sustained R&D investment and technological achievements.
• Integrated R&D-to-manufacturing footprint enabling clinical development, pilot-scale production, and commercial supply for transdermal products.
• Patent and product portfolio oriented toward drug-delivery platforms, high-end preparations, and combination TCM-modern formulations.

• Scale transdermal R&D: expand formulation platforms to increase pipeline breadth (12 active candidates) and accelerate IND/clinical milestones.
• Commercial expansion: grow distribution of the five approved percutaneous/high-end products across hospital channels and community pharmacies in Tier 1-3 cities.
• Quality and compliance: maintain GMP expansion and clinical evidence generation to support premium positioning and potential export opportunities.
• Technology integration: fuse TCM active ingredients with controlled-release transdermal matrices to create differentiated therapeutic profiles.

Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ) - Vision Statement

• R&D intensity: In 2022 the company allocated approximately 7.5% of total revenue to research and development, demonstrating a long-term commitment to novel therapies and product pipeline expansion.
• Ethical standards: Professionalism and trust guide interactions with patients, healthcare providers, distributors, and regulatory bodies.
• Collaborative growth: Strategic alliances with domestic and international pharmaceutical firms and research institutions accelerate translational research and market access.
• Inclusive culture: Tolerance for diverse perspectives fosters creative problem-solving across R&D, manufacturing, and commercialization functions.
• Social responsibility: Active donations, disaster relief participation, student sponsorships, and poverty alleviation programs anchor corporate citizenship.

• Innovation - sustained funding for pipeline projects, new molecular entities, and manufacturing process improvements; 2022 R&D spend (~¥81 million) prioritized clinical-stage programs and quality systems.
• Integrity - compliance programs, quality control benchmarks, and transparent reporting ensure patient safety and stakeholder trust.
• Cooperation - bilateral partnerships, joint research agreements, and licensing deals broaden therapeutic reach and optimize resource use.
• Tolerance - hiring and internal cross-functional forums promote diversity of expertise and viewpoint integration for robust decision-making.
• Responsibility - targeted CSR programs (anti-epidemic aid, disaster relief, student sponsorship, poverty alleviation) reflect recurring annual allocations and mobilization of company resources.